



Toujeo[®] (insulin glargine) – Expanded indication

- On November 26, 2019, the [FDA approved](#) Sanofi's [Toujeo \(insulin glargine\)](#), to improve glycemic control in adults and pediatric patients 6 years and older with diabetes mellitus (DM).
 - Previously, Toujeo was approved for the same indication in adults.
 - Toujeo is not recommended for the treatment of diabetic ketoacidosis.
- The FDA approval of the expanded indication for Toujeo was based on studies in adults with DM and a 26-week, open-label study of 463 pediatric patients with type 1 DM. Patients were randomized to basal-bolus treatment with Toujeo or [Lantus[®] \(insulin glargine\)](#).
 - At week 26, the difference in HbA_{1c} reduction from baseline between Toujeo and Lantus was 0.02% (95% CI: -0.16%, 0.20%) and met the prespecified noninferiority margin of 0.3%.
- The recommended starting dose of Toujeo in insulin-naïve pediatric and adult patients with type 1 DM is approximately one-third to one-half of the total daily insulin dose given subcutaneously (SC) once daily. As a general rule, 0.2 to 0.4 units of insulin per kilogram of body weight can be used to calculate the initial total daily insulin dose.
- The recommended starting dose of Toujeo in insulin-naïve pediatric and adult patients with type 2 DM is 0.2 units per kilogram of body weight SC once daily.
- The dosage of Toujeo should be individualized and titrated based on the individual's metabolic needs, blood glucose monitoring results, and glycemic control goal.
- The dose of Toujeo should be titrated no more frequently than every 3 to 4 days.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.